Please note that this summary was posted more than 5 years ago. More recent research findings may have been published.
This is a plain English summary of an original research article. The views expressed are those of the author(s) and reviewer(s) at the time of publication.
Testing for and then treating pregnant women with mild or “subclinical” underactive thyroid did not improve pregnancy outcomes, newborn baby outcomes, or the child’s IQ at three to five years.
A clearly underactive thyroid (clinical hypothyroidism) in pregnancy has been linked with various adverse outcomes for the mother and baby, including pre-eclampsia, preterm birth, congenital defects and neurodevelopmental delay. This needs treatment. However, there has been debate around the harms and benefits from treating only mildly abnormal blood test results in women who do not show signs of thyroid problems, subclinical hypothyroidism.
These two linked trials randomised 1,203 women with borderline abnormal levels of thyroid-related hormones (but not “clinical” or “overt” hypothyroidism) to receive thyroid replacement treatment, with levothyroxine, or placebo. Treatment had no benefits for mother or baby, including the main outcome of child IQ by three to five years of age.
This supports current UK practice, which does not routinely screen all pregnant women for subclinical thyroid dysfunction.
Why was this study needed?
The thyroid gland produces hormones that help to regulate the body’s metabolism. Around 15 in every 1,000 women in the UK have an underactive thyroid though fewer women in pregnancy have the condition, about four in every 1,000 women. People with definite (clinical) low thyroid hormones can feel tired or depressed, gain weight and experience muscle aches, it can also lead to high cholesterol. In pregnancy there can also be harms to the unborn child including failure to develop normally and reduced intelligence. Therefore, clinical hypothyroidism during pregnancy is usually treated with levothyroxine, a drug that replaces thyroid hormone.
However, the exact risks associated with borderline blood levels, and the cut-off thyroid levels for treatment are not clear. There could even be harms from unnecessarily treating women with sub-clinical hypothyroidism. About 5% of women screened in pregnancy would be labelled as having sub-clinical hypothyroidism, depending on definitions.
What did this study do?
This study comprised two randomised controlled trials of women identified through antenatal clinic screening prior to 20 weeks of pregnancy. They were found to have only one abnormal of the two indicator hormones; both are abnormal in clinical hypothyroidism. The practicalities of screening meant that women were at 16 weeks gestation when they started treatment.
One trial included 677 women with “subclinical” hypothyroidism defined by normal thyroid hormone (thyroxine, T4) levels, but high thyroid stimulating hormone (TSH) levels of 4.00mU/L or greater. These women were randomised to either 100µg of levothyroxine or a placebo, with dose adjustment.
The other trial included 526 women with hypothyroxinemia, defined by low thyroxine (T4) levels (less than 0.86ng/dL) but normal TSH levels. They were randomised to either 50µg of levothyroxine or placebo, with dose adjustment.
The main outcome examined was the child’s IQ at three to five years, but several others were also measured.
What did it find?
- Levothyroxine treatment during pregnancy had no significant effect on child IQ at age three to five years. In the high TSH trial the difference in IQ score was zero (95% confidence interval [CI] -3 to 2), and in the low T4 trial, -1 (95% CI -4 to 1).
- Treatment also did not affect the child’s cognitive, motor, language, information processing ability or their behaviour up to five years of age.
- Levothyroxine treatment had no effect on the frequency of any other adverse maternal or neonatal outcomes in either trial, such as pre-eclampsia, preterm birth, birth weight, neonatal intensive care admission, miscarriage or stillbirth.
What does current guidance say on this issue?
There is no UK guidance to screen for hypothyroidism from the National Screening Committee or in the NICE antenatal guideline. Nor is there guidance to treat sub-clinical hypothyroidism
NICE Clinical Knowledge Summaries outline various criteria for testing thyroid function for women who are pregnant or planning a pregnancy. This includes testing for those over 30 years of age, with thyroid swelling or symptoms of thyroid dysfunction, with a personal or family history of a thyroid condition, with diabetes, morbid obesity or an autoimmune condition, after head or neck radiotherapy, or after past miscarriage or preterm delivery.
What are the implications?
This large trial indicates that treating subclinical hypothyroidism or hypothyroxinemia does not affect pregnancy outcomes or newborn outcomes, or affect the child’s neurodevelopment up to five years of age. This agrees with the previous large UK CATS trial of screening that reported while this study was underway.
This suggests that there is no advantage to treating women in this subclinical and asymptomatic group, and therefore no benefit in screening. This aligns with current UK practice, which does not routinely screen all pregnant women for thyroid dysfunction.
The results do not apply to women with overt thyroid disorders or to those discovered in early pregnancy before 16 weeks. There could be a small benefit to the developing foetus if the problem were detected and treatment started very early in pregnancy, but this is unknown.
Citation and Funding
Casey BM, Thom EA, Peaceman AM, et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal–Fetal Medicine Units Network. Treatment of Subclinical Hypothyroidism or Hypothyroxinemia in Pregnancy. N Engl J Med. 2017;376(9):815-25.
This trial was supported by grants from the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the US National Institute of Neurological Disorders and Stroke.
Bibliography
BTF. Thyroid in Pregnancy - FAQs. Harrogate: British Thyroid Foundation; 2015.
CKS. Hypothyroidism: screening for hypothyroidism. London: National Institute for Health and Care Excellence; 2016.
CKS. Hypothyroidism: assessment. London: National Institute for Health and Care Excellence; 2016.
CKS. Hypothyroidism: levothyroxine. London: National Institute for Health and Care Excellence; 2016.
NHS Choices. Underactive thyroid (hypothyroidism). London: Department of Health; 2015.
Produced by the University of Southampton and Bazian on behalf of NIHR through the NIHR Dissemination Centre
NIHR Evidence is covered by the creative commons, CC-BY licence. Written content and infographics may be freely reproduced provided that suitable acknowledgement is made. Note, this licence excludes comments and images made by third parties, audiovisual content, and linked content on other websites.
